113D7756-712E-4EB4-9993-BBAF3C41AFEF
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 5.059132720105125
- age_years
- 57
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.626
- TNFA_SIGNALING_VIA_NFKB+0.594
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.589
- IL6_JAK_STAT3_SIGNALING+0.584
- INTERFERON_ALPHA_RESPONSE+0.584
- INTERFERON_GAMMA_RESPONSE+0.557
- HYPOXIA+0.494
- MYC_TARGETS_V1+0.493
- E2F_TARGETS+0.486
- ALLOGRAFT_REJECTION+0.480
Top 10 suppressed
- KRAS_SIGNALING_DN-0.348
- PANCREAS_BETA_CELLS-0.259
- SPERMATOGENESIS-0.214
- BILE_ACID_METABOLISM-0.140
- MYOGENESIS-0.103
- OXIDATIVE_PHOSPHORYLATION-0.030
- HEDGEHOG_SIGNALING-0.005
- ESTROGEN_RESPONSE_EARLY+0.078
- APICAL_SURFACE+0.081
- PEROXISOME+0.113
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.987 |
| 2 | SRR934932 | — | — | 0.982 |
| 3 | SRR934903 | — | — | 0.980 |
| 4 | SRR934913 | — | — | 0.977 |
| 5 | SRR934750 | — | — | 0.977 |
| 6 | 4B93A447-E626-4040-9BA0-1EEAB3764C6B | — | — | 0.976 |
| 7 | SRR934926 | — | — | 0.976 |
| 8 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.975 |
| 9 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.975 |
| 10 | SRR934782 | — | — | 0.974 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.626 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.594 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.589 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.584 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.584 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.557 | Idelalisib | — uncovered |
| HYPOXIA | 0.494 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.493 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.486 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| COAGULATION | 0.472 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.456 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.455 | Idelalisib | — uncovered |
| APOPTOSIS | 0.450 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.433 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.431 | Inavolisib | — uncovered |
| COMPLEMENT | 0.413 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.413 | Idelalisib | — uncovered |